Real world, observational study evaluating efficacy and toxicity of Immune checkpoint inhibitors in patients with tumors
Latest Information Update: 19 Feb 2020
At a glance
- Drugs Atezolizumab (Primary) ; Durvalumab (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma; Non-small cell lung cancer; Renal cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 19 Feb 2020 New trial record